Parkinson’s UK Invests Up to £800,000 in New Trial Testing GDNF

Parkinson’s UK Invests Up to £800,000 in New Trial Testing GDNF

287838

Parkinson’s UK Invests Up to £800,000 in New Trial Testing GDNF

Parkinson’s UK is paving the way for a future clinical trial that will continue to test a naturally occurring protein, the glial cell line-derived neurotrophic factor or GDNF, as a potential therapy for slowing Parkinson’s disease progression. The new trial will follow a 2019 clinical study of GDNF, of which Parkinson’s UK was the major financial backer. While the results were inconclusive, they supported GDNF’s potential for regenerating dopamine-producing neurons in Parkinson’s and easing patients’…

You must be logged in to read/download the full post.